Brink's Receives CMA Acceptance in Principle of Proposed Remedy Relating to Pending Acquisition of NCR Atleos
Globe Newswire•08/10/2026•05:09 ET
7
Key Highlights
- ➤CMA accepts in principle NoteMachine/TestLink UK divestiture remedy for NCR Atleos acquisition
- ➤NCR Atleos acquisition remains on track to close early in Q1 2027
- ➤Brink’s continues to expect $200 million annual run-rate cost synergies within three years
- ➤NoteMachine/TestLink UK sale process advances with multiple prospective buyers engaged
Expert Statements
Mark Eubanks, President and Chief Executive Officer of Brink’s
“We are pleased with the CMA’s acceptance in principle of the proposed remedy, as this represents a significant step forward, and we appreciate the CMA's constructive and timely engagement throughout the process.”
Mark Eubanks, President and Chief Executive Officer of Brink’s
“The potential sale of NoteMachine/TestLink UK was a remedy that was contemplated in the financial metrics that Brink’s has previously disclosed and does not impact the $200 million in annual run-rate cost synergies that we continue to expect to achieve within three years of closing the transaction.”
Mark Eubanks, President and Chief Executive Officer of Brink’s
“We continue to make progress towards the successful completion of our pending acquisition of NCR Atleos and look forward to positioning the combined business to deliver enhanced customer solutions and accelerate our value creation strategy.”
Divestiture of NoteMachine/TestLink UK to avoid a CMA Phase 2 referral
Acquisition of NCR Atleos remains on track to close early in the first quarter of 2027
Get started
Create a free account to read the full story.